**Research-Only Disclaimer:** All compounds discussed on this page are sold by BioPharma for in vitro research purposes only. Not intended for human or veterinary use. This content is for informational purposes and does not constitute medical advice.

This GW-501516 research guide covers one of the most unique compounds in performance research — and it’s not even a SARM. Cardarine (GW-501516) operates through entirely different pathways, targeting PPARδ receptors to unlock endurance and fat metabolism effects that no androgenic compound can replicate.

If you’re building out a research program focused on stamina, metabolic output, or fat oxidation studies, GW-501516 is the compound the data keeps pointing to. This guide breaks down the full scope of GW-501516 PPAR research: mechanism, study results, how it differs from SARMs, safety considerations, and where it fits in the broader SARMs research guide ecosystem.

What Is GW-501516 (Cardarine)?

GW-501516 — commonly called Cardarine — is a PPARδ (peroxisome proliferator-activated receptor delta) agonist. It was developed in a collaboration between GlaxoSmithKline and Ligand Pharmaceuticals during the early 2000s as part of a program investigating metabolic disease therapies.

Here’s the critical distinction: GW-501516 is NOT a SARM. It does not bind to or activate androgen receptors. It has zero anabolic activity on muscle tissue through androgenic pathways. What it does instead is activate PPARδ, a nuclear receptor that regulates genes involved in fatty acid oxidation, energy expenditure, and skeletal muscle fiber-type switching.

This makes GW-501516 a completely different research tool — one focused on metabolic performance rather than anabolic signaling. In the cardarine canada research market, it’s gained massive attention precisely because it fills a gap that SARMs can’t: endurance and fat metabolism optimization without any androgenic pathway involvement.

How GW-501516 Works: PPARδ Mechanism of Action

Understanding GW-501516 means understanding PPARδ. Here’s what the research reveals about this mechanism:

PPARδ activation cascade:

  • Fatty acid oxidation upregulation: GW-501516 activates genes that shift cellular energy metabolism from glucose to fatty acid oxidation — essentially reprogramming cells to burn fat as primary fuel
  • Mitochondrial biogenesis: Stimulates production of new mitochondria in skeletal muscle, increasing total cellular energy capacity
  • Skeletal muscle fiber switching: Promotes conversion of Type IIb (fast-twitch/glycolytic) fibers toward Type I (slow-twitch/oxidative) phenotype — the muscle fiber profile associated with endurance performance
  • AMPK pathway interaction: GW-501516 research suggests cross-talk with AMPK signaling (the cell’s energy-sensing pathway), amplifying metabolic effects
  • No androgen receptor activity: Zero interaction with AR — no anabolic signaling, no suppression, no androgenic effects

This metabolic reprogramming is why gw501516 endurance research consistently shows dramatic improvements in stamina metrics. The compound doesn’t just increase energy — it changes how cells produce and use energy at the genetic level.

What the Research Shows: GW-501516 Study Results

The GW-501516 research base includes both preclinical and early clinical studies. Here’s what the data reveals:

Preclinical Endurance Studies (Animal Models)

The landmark preclinical research on GW-501516 produced some of the most striking results in performance compound research:

  • 68% increase in running endurance in mice treated with GW-501516 compared to controls (Narkar et al., 2008) — one of the most cited findings in PPAR research
  • Significant resistance to weight gain even on high-fat diet protocols in treated animal groups
  • Improved insulin sensitivity and glucose tolerance in metabolic disease models
  • Fiber-type switching confirmed in muscle tissue analysis, with measurable increases in oxidative (Type I) fiber content

Fat Metabolism Research

GW-501516 PPAR research has produced compelling data on lipid metabolism:

  • Increased expression of genes involved in fatty acid transport and β-oxidation
  • Reduced adipose tissue accumulation in multiple animal study models
  • Enhanced cholesterol profiles (increased HDL, decreased LDL and triglycerides) in some preclinical observations
  • Preferential use of fat stores over glycogen during sustained activity models

Human Research and Clinical Development

GSK pursued GW-501516 into early clinical development for metabolic diseases:

  • Phase 1 and Phase 2 trials showed measurable effects on lipid markers and metabolic parameters
  • Development was discontinued after preclinical toxicology studies in rats showed tumor formation at very high doses over extended exposure periods (2-year rodent carcinogenicity study)

Important context on the carcinogenicity data: The tumor findings occurred at doses significantly higher than those used in earlier studies, over a 2-year duration in rats. Some researchers and toxicologists have debated the relevance of these findings to short-term, low-dose human exposure models. However, the carcinogenicity signal is a critical data point that any GW-501516 researcher must acknowledge and account for.

GW-501516 vs. SARMs: A Different Research Tool Entirely

Because GW-501516 is so frequently grouped with SARMs (despite being a completely different compound class), comparison is essential:

| Feature | GW-501516 (Cardarine) | LGD-4033 (SARM) | MK-2866 (SARM) |

|—|—|—|—|

| Compound Class | PPARδ Agonist | SARM | SARM |

| Primary Pathway | Metabolic/Fat Oxidation | Androgen Receptor | Androgen Receptor |

| Endurance Research | ★★★★★ Best in class | ★★☆☆☆ Minimal | ★★☆☆☆ Minimal |

| Anabolic Mass | ☆☆☆☆☆ None | ★★★★★ Highest | ★★★☆☆ Moderate |

| Fat Metabolism | ★★★★★ Strongest | ★★★☆☆ Indirect | ★★☆☆☆ Mild |

| Androgen Suppression | None | Moderate-High | Low-Moderate |

| Safety Concerns | Carcinogenicity signal at high/long doses | Standard SARM profile | Best-characterized SARM |

GW-501516 fills a completely different research niche. If you want anabolic output, you need a SARM. If you want endurance and metabolic data, GW-501516 is the play. Many researchers combine the two pathways — explore the SARMs research guide for the full compound landscape.

Research Protocols: What the Literature Suggests

Published GW-501516 research protocols typically follow these frameworks:

Standard research concentration ranges:

  • 5 mg/day — Low-end dose used in some clinical work; measurable metabolic and lipid effects
  • 10 mg/day — Most common research dose; strong endurance and fat oxidation data at this concentration
  • 15–20 mg/day — Higher-range doses used in performance research logs; increased metabolic output but higher exposure

Study duration patterns:

  • Short-term: 2–4 weeks for acute metabolic and endurance response data
  • Standard: 6–8 weeks for most performance research protocols
  • Extended: 10–12+ weeks (longer exposures should account for carcinogenicity data and plan appropriate monitoring)
  • No post-cycle recovery needed: Since GW-501516 does not suppress androgen production, there is no HPTA recovery requirement — a unique advantage in research design

Important: These references come from published literature and community research logs. BioPharma sells GW-501516 strictly for in vitro research use only.

Cardarine Canada: Sourcing Reliable GW-501516

The cardarine canada market has specific challenges. Because GW-501516 operates in a regulatory gray area and was never brought to market as a pharmaceutical, the research compound supply is rife with quality issues.

What your GW-501516 supply must deliver:

  • Verified compound identity — too many “Cardarine” products contain wrong or adulterated compounds
  • 98%+ purity with CoA — you can’t afford confounding variables in PPAR research
  • Accurate concentration labeling — metabolic studies are dose-sensitive; imprecise dosing corrupts your data
  • Stable formulation — GW-501516 degrades under certain conditions; your supplier needs to handle and store it properly

BioPharma supplies GW-501516 with full third-party CoA verification, guaranteed purity, and the handling standards your research requires. Shop GW-501516 →

GW-501516 in Combination Research: Stacking Protocols

Because GW-501516 targets a completely different pathway than SARMs, it’s one of the most popular compounds for multi-pathway research stacks. Common combinations in published and community research:

Cardarine + SARM stacks (research purposes only):

  • GW-501516 + MK-2866 — Tissue preservation + metabolic optimization; popular in recomposition research
  • GW-501516 + LGD-4033 — Anabolic mass + endurance/fat metabolism; covers both major performance pathways
  • GW-501516 + MK-677 — Metabolic enhancement + growth hormone secretagogue; see the MK-677 research guide for IGF-1 pathway details

For the newest compound in the endurance research space, the SLU-PP-332 research guide covers a next-gen mitochondrial uncoupler that’s gaining attention alongside GW-501516.

Frequently Asked Questions

Is GW-501516 a SARM?

No. GW-501516 (Cardarine) is a PPARδ agonist, not a selective androgen receptor modulator. It does not bind to androgen receptors and has no anabolic or androgenic activity. It’s commonly grouped with SARMs in retail and community discussions, but the mechanism is entirely different. BioPharma sells GW-501516 for in vitro research purposes only.

Why did GW-501516 clinical development stop?

GlaxoSmithKline discontinued development after a 2-year rodent carcinogenicity study showed tumor formation at very high doses. This is a critical data point for researchers to consider. The debate about relevance to typical research doses continues, but the safety signal cannot be dismissed.

Does GW-501516 suppress testosterone?

No. Because GW-501516 operates through PPARδ rather than androgen receptors, it has no effect on endogenous testosterone production. This is one of its key differentiating features compared to SARMs in research design.

What makes GW-501516 different from endurance-boosting SARMs?

SARMs improve endurance only indirectly (through muscle growth or tissue preservation). GW-501516 directly reprograms cellular energy metabolism at the genetic level — shifting fuel utilization from glucose to fat oxidation, increasing mitochondrial density, and converting muscle fibers to oxidative phenotypes. This produces fundamentally different endurance data than any SARM can generate.

Can GW-501516 be combined with SARMs in research?

Yes. Because GW-501516 and SARMs target completely different pathways (PPARδ vs. androgen receptors), they don’t compete or interfere with each other. Combined protocols are common in multi-pathway research. The SARMs research guide covers SARM options for stacking.

Is Cardarine legal in Canada for research?

GW-501516 can be legally sold and purchased for in vitro research purposes in Canada. It is not approved for human consumption. Researchers should verify institutional and local regulatory requirements before purchasing.

Related Research Guides

Get GW-501516 for Your Research

When your research demands the most powerful metabolic and endurance compound available, GW-501516 is the answer. BioPharma supplies research-grade Cardarine with verified purity, full CoA documentation, and the precision your protocols require.

Shop GW-501516 →

All compounds discussed on this page are sold by BioPharma for in vitro research purposes only. Not intended for human or veterinary use. This content is for informational purposes and does not constitute medical advice. Results referenced are from published research and may not reflect outcomes from your specific protocols.